Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00132795 · ClinicalTrials.gov registry record · Phase 2

Using Telephone Technology to Prevent Relapse After Alcoholism Treatment

A Phase 2 study, sponsored by University of Vermont.

Completed
Registry status
Phase 2
Development phase
158
Enrollment target

NCT00132795: Completed Phase 2 study, sponsored by University of Vermont.

NCT00132795 is a Phase 2 study that has completed, run by University of Vermont. The registered enrollment target is 158 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00132795, a Phase 2 study, has completed, sponsored by University of Vermont.

COMPLETED
Registry status
Phase 2
Development phase
158 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether a telephone based self-help program will prevent relapse among individuals undergoing standard substance abuse treatment.

Primary Outcome

drinks per day, drinks per drinking day, percent days abstinent, heavy drinking days

Interventions

  • BEHAVIORAL control group
  • BEHAVIORAL Daily monitoring of alcohol & drug use, & therapy skills

Trial Details

FieldValue
Enrollment Target 158 participants
Start Date 2005-05
Est. Completion 2010-07
Phase Phase 2
University of Vermont

162 total trials

What the finished NCT00132795 record still lists

NCT00132795 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher).

The record links to 0 conditions, and to 2 interventions - of which control group is the first listed.

NCT00132795 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00132795 about?

NCT00132795 is a clinical study titled "Using Telephone Technology to Prevent Relapse After Alcoholism Treatment". The purpose of this study is to determine whether a telephone based self-help program will prevent relapse among individuals undergoing standard substance abuse treatment.

What is the current status of trial NCT00132795?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2005-05. Estimated completion is 2010-07.

What interventions are being tested in trial NCT00132795?

The interventions under investigation include: control group (BEHAVIORAL), Daily monitoring of alcohol & drug use, & therapy skills (BEHAVIORAL).

Who is sponsoring clinical trial NCT00132795?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00132795's enrollment target sits among peer trials

158 443rd of 2000 higher than 1,558 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04486833 · 158 participants · Phase 1

    Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

  • NCT04697966 · 158 participants · NA

    Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents

  • NCT04969835 · 158 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

  • NCT05230732 · 158 participants · NA

    Neuromodulation of Inflammation and Endothelial Function

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00132795, the US trial registry maintained by the National Library of Medicine. NCT00132795 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.